Biapenem–fosfomycin shows enhanced in vitro activity compared with meropenem–fosfomycin against NDM-producing Enterobacterales
- 1Department of Microbiology, St. Marianna University School of Medicine, Kanagawa, Japan
- 2Department of Clinical Laboratory Technology, St. Marianna University Hospital, Kanagawa, Japan
- 3Department of Infectious Diseases, St. Marianna University School of Medicine, Kanagawa, Japan
Abstract
Treatment options for New Delhi metallo-β-lactamase-producing Enterobacterales (NDME) remain limited, and the clinical relevance of fosfomycin–carbapenem combinations has not been fully established. We evaluated whether biapenem–fosfomycin provides greater in vitro activity than meropenem–fosfomycin. A total of 54 clinical NDME isolates (Escherichia coli, n = 22; Klebsiella pneumoniae, n = 21; Enterobacter cloacae complex, n = 11) collected in Bangladesh and Japan were analyzed. Antimicrobial susceptibility testing, checkerboard assays, checkerboard-derived cumulative inhibition analyses, time–kill assays, and assessment of fosfomycin-resistant subpopulations were performed. Biapenem exhibited lower MICs than meropenem across all species. Biapenem–fosfomycin demonstrated higher rates of synergy than meropenem–fosfomycin, particularly in E. coli (73% vs 45%). At concentration pairs corresponding to median minimum Fractional Inhibitory Concentration Index (mFICI) values, a greater proportion of isolates was inhibited at low biapenem concentrations in the presence of fosfomycin, whereas this effect was more limited with meropenem. At a fixed carbapenem concentration of 1 μg/mL, ≥90% inhibition was achieved at lower fosfomycin concentrations with biapenem–fosfomycin than with meropenem–fosfomycin. Time–kill analyses demonstrated that mFICI-based conditions resulted in regrowth, whereas MIC/MIC combinations of biapenem–fosfomycin maintained bacterial suppression over 24 h. Fosfomycin alone was associated with frequent recovery of fosfomycin-resistant subpopulations, whereas biapenem–fosfomycin reduced their recovery under the tested conditions. Biapenem–fosfomycin demonstrated favorable in vitro activity compared with meropenem–fosfomycin against NDME. These findings indicate that checkerboard-defined synergy should be interpreted together with cumulative inhibition profiles, killing kinetics, and resistant-subpopulation data.
IMPORTANCE: Treating infections caused by New Delhi metallo-β-lactamase (NDM)-producing Enterobacterales remains a major global challenge because therapeutic options are limited. Fosfomycin–carbapenem combinations are frequently assessed using checkerboard-based Fractional Inhibitory Concentration Index (FICI), but this screening approach does not fully describe time-dependent killing, regrowth, or the recovery of resistant subpopulations. In this study, we compared biapenem–fosfomycin with meropenem–fosfomycin using checkerboard assays and checkerboard-derived cumulative inhibition analysis and further characterized biapenem–fosfomycin using time–kill assays and fosfomycin-resistant subpopulation assessment. Biapenem–fosfomycin showed more favorable in vitro activity than meropenem–fosfomycin under the tested conditions. These findings support further evaluation of biapenem–fosfomycin using dynamic pharmacokinetic models that better reproduce human drug exposure profiles.
Related
- In Vitro and In Vivo Efficacy of the Broad-Spectrum β-Lactamase Inhibitor APC24-7 in Combination with Meropenem Against Carbapenem-Resistant Enterobacterales.
- Fosfomycin monotherapy for the treatment of a complicated prostatic abscess caused by KPC-producing carbapenem-resistant Escherichia coli
- Persistence of Extended Spectrum β-Lactamase-Producing Enterobacterales in the Gut Microbiome of Healthy Newborns
- JDB-1-200, an Atypically Modified Carbapenem with Standalone In Vitro Activity against KPC-Producing Enterobacterales.
- Systematic surveillance of Carbapenemase-producing Enterobacterales reveals persistent spread of IMP-4 IncM2 plasmids in New Caledonia
BibTeX
@article{okanda2026biapenemfosfomycin,
title = {{Biapenem–fosfomycin shows enhanced in vitro activity compared with meropenem–fosfomycin against NDM-producing Enterobacterales}},
author = {Takashi Okanda and Daishu Fukushima and Natsuki Yumura and Niinyo Nakajima and Takuro Koshikawa and Tadatomo Oyanagi and Tomonori Takano and Tetsuo Yamaguchi and Hiroyuki Kunishima and Mitsuo Kaku and Hiromu Takemura},
journal = {Microbiology Spectrum},
year = {2026},
month = oct,
doi = {10.1128/spectrum.01350-26},
url = {https://doi.org/10.1128/spectrum.01350-26},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Biapenem–fosfomycin shows enhanced in vitro activity compared with meropenem–fosfomycin against NDM-producing Enterobacterales
AU - Takashi Okanda
AU - Daishu Fukushima
AU - Natsuki Yumura
AU - Niinyo Nakajima
AU - Takuro Koshikawa
AU - Tadatomo Oyanagi
AU - Tomonori Takano
AU - Tetsuo Yamaguchi
AU - Hiroyuki Kunishima
AU - Mitsuo Kaku
AU - Hiromu Takemura
PY - 2026
DA - 2026/10/08
JO - Microbiology Spectrum
DO - 10.1128/spectrum.01350-26
UR - https://doi.org/10.1128/spectrum.01350-26
AB - Treatment options for New Delhi metallo-β-lactamase-producing Enterobacterales (NDME) remain limited, and the clinical relevance of fosfomycin–carbapenem combinations has not been fully established. We evaluated whether biapenem–fosfomycin provides greater in vitro activity than meropenem–fosfomycin. A total of 54 clinical NDME isolates (Escherichia coli, n = 22; Klebsiella pneumoniae, n = 21; Enterobacter cloacae complex, n = 11) collected in Bangladesh and Japan were analyzed. Antimicrobial susceptibility testing, checkerboard assays, checkerboard-derived cumulative inhibition analyses, time–kill assays, and assessment of fosfomycin-resistant subpopulations were performed. Biapenem exhibited lower MICs than meropenem across all species. Biapenem–fosfomycin demonstrated higher rates of synergy than meropenem–fosfomycin, particularly in E. coli (73% vs 45%). At concentration pairs corresponding to median minimum Fractional Inhibitory Concentration Index (mFICI) values, a greater proportion of isolates was inhibited at low biapenem concentrations in the presence of fosfomycin, whereas this effect was more limited with meropenem. At a fixed carbapenem concentration of 1 μg/mL, ≥90% inhibition was achieved at lower fosfomycin concentrations with biapenem–fosfomycin than with meropenem–fosfomycin. Time–kill analyses demonstrated that mFICI-based conditions resulted in regrowth, whereas MIC/MIC combinations of biapenem–fosfomycin maintained bacterial suppression over 24 h. Fosfomycin alone was associated with frequent recovery of fosfomycin-resistant subpopulations, whereas biapenem–fosfomycin reduced their recovery under the tested conditions. Biapenem–fosfomycin demonstrated favorable in vitro activity compared with meropenem–fosfomycin against NDME. These findings indicate that checkerboard-defined synergy should be interpreted together with cumulative inhibition profiles, killing kinetics, and resistant-subpopulation data. IMPORTANCE: Treating infections caused by New Delhi metallo-β-lactamase (NDM)-producing Enterobacterales remains a major global challenge because therapeutic options are limited. Fosfomycin–carbapenem combinations are frequently assessed using checkerboard-based Fractional Inhibitory Concentration Index (FICI), but this screening approach does not fully describe time-dependent killing, regrowth, or the recovery of resistant subpopulations. In this study, we compared biapenem–fosfomycin with meropenem–fosfomycin using checkerboard assays and checkerboard-derived cumulative inhibition analysis and further characterized biapenem–fosfomycin using time–kill assays and fosfomycin-resistant subpopulation assessment. Biapenem–fosfomycin showed more favorable in vitro activity than meropenem–fosfomycin under the tested conditions. These findings support further evaluation of biapenem–fosfomycin using dynamic pharmacokinetic models that better reproduce human drug exposure profiles.
SN - 2165-0497
ER -